查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1837138

结核病检测市场按检测类型、最终用户、技术、样本类型、分销管道和应用划分－2025-2032 年全球预测

Tuberculosis Testing Market by Test Type, End User, Technology, Sample Type, Distribution Channel, Application - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年结核病检测市场规模将成长至 38.2 亿美元，复合年增长率为 6.10%。

主要市场统计数据
基准年2024年 23.8亿美元
预计2025年 25.2亿美元
预测年份：2032年 38.2亿美元
复合年增长率（%） 6.10%

全面说明当前结核病诊断动态，整合临床实务、技术途径、供应考量和采购重点

本执行摘要综合了跨临床路径的关键发展，这些发展影响结核病诊断实践、技术应用和最终用户的优先事项。它提供了对不断发展的诊断方法、监管变化、分销动态以及影响实验室、医院和诊所的营运压力的统一视图。本文件特意强调了相关人员在供应链审查日益严格的情况下必须调整采购、临床工作流程和创新蓝图的实际意义。

本概述文件基于最新的监管更新、供应链模式和临床指南，为临床领导者和商业策略制定者提供了清晰的决策背景。它根据检测类型和技术区分了诊断方法，并阐明了样本类型和最终用户环境如何影响检测的选择和使用。最终，本介绍为后续的针对性建议和营运行动奠定了基础，以帮助各机构在其结核病检测策略中优先考虑韧性、诊断准确性和以患者为中心的可及性。

技术融合、检测分散化以及临床期望的变化如何改变整个医疗环境中的诊断和营运重点

由于分子技术的进步、液检体检测的创新以及加速的即时诊断 (POC) 解决方案（可缩短获得结果的时间），结核病诊断领域正在发生重大变化。这些技术进步也伴随着临床期望的改变。临床医生越来越期望获得快速、可操作的结果，以便指导即时治疗决策和接触者追踪介入。因此，诊断开发正转向兼顾灵敏度、操作简便性和快速週转的平台。

同时，诊断生态系统正在适应新的分发和存取模式，优先考虑分散式检查。虽然参考实验室仍然是复杂检测的核心，但医院和诊所越来越寻求能够融入常规工作流程的快速诊断平台。基于培养的方法不断改进，而核酸扩增技术和免疫诊断技术也正在优化，以便在各种医疗环境中广泛应用。这种转变需要研发、监管事务和商业营运之间的策略合作，以确保新型诊断方法能够满足临床和物流需求。

关税主导的供应链调整和策略采购转变重塑了诊断服务的采购行为、製造足迹和库存弹性

美国将于2025年提高关税，这严重扰乱了全球诊断供应链，尤其是对结核病检测工作流程至关重要的组件和耗材。进口试剂、检测试剂套件和特定设备的关税增加了到岸成本，凸显了采购敏捷性的重要性。直接结果是，实验室和医院的采购团队审查了其供应商组合和合约条款，以减轻短期成本影响并保持检测的连续性。

作为应对，许多组织扩大了在地采购策略，并加快了替代供应商的资格认证流程，以减少对受关税影响的进口途径的依赖。这种转变促使他们重新审视库存政策，并转向对常用耗材（如核酸萃取试剂套件和培养基）进行策略性储备。同时，製造商面临重新评估其全球生产基地的压力，需要优先考虑区域製造投资和外包製造外包，以避免关税的影响。监管途径和供应验证成为关注的焦点，因为替代供应商和新本地化的生产线需要及时和严格的性能检验。总而言之，这些调整表明需要灵活的采购惯例、多样化的供应商生态系统和综合的监管计划，以避免与关税相关的中断，同时保持诊断的可靠性和临床的连续性。

透过整合细分框架，将测试模式、最终用户需求、检体物流和分销管道连结起来，优先考虑临床和商业策略

了解细分市场对于制定结核病诊断产品开发、商业化和临床应用策略至关重要。在评估检测类型时，相关人员必须区分培养检测、免疫测定、分子诊断和快速诊断。其中，有一些重要的亚型，例如用于层析法检测的液体培养、固体培养、ELISA、Western blot免疫检测测定、线性探针检测和PCR，以及用于快速诊断的色谱法和侧向层析。这些细分市场会影响通量、技术技能要求以及与现有实验室基础设施的兼容性，因此指南在何处投资自动化和培训以获得最大的营运效益。

最终用户细分进一步细化了优先级，因为诊所、医院和参考实验室对週转时间、批次和复杂性容忍度有不同的需求。跨基于培养的技术、免疫诊断、脂阿拉伯甘露聚醣检测和核酸增幅检查的技术细分为产品创新途径和监管策略提供了框架，因为不同的技术面临不同的验证要求和临床证据阈值值。血液、痰和尿液等检体类型会影响检体采集物流、生物安全通讯协定以及适合照护现场或集中检测。分销管道动态，例如诊断实验室、医院药房和线上药房模式，决定了采购週期和报销接触点。最后，活动性结核病和潜伏性结核病之间的应用细分需要不同的表现特征和解释框架。整合这些细分层可让相关人员确定投资优先顺序、定义临床部署模型并使证据产生与最关键的设定和用例保持一致。

区域监管协调、基础设施多样性和公共卫生优先事项将如何推动全球不同的采用途径和交付策略

区域动态既影响诊断技术的采用路径，也影响供应商面临的营运需求。在美洲，重点是整合实验室网络，确保检测核准的监管一致性，并将诊断技术纳入更广泛的公共卫生工作。这些优先事项正在影响采购时间表，以及与现有实验室资讯系统相容的有效、可互通解决方案的需求。

在欧洲、中东和非洲，监管协调工作和多样化的医疗保健资金筹措模式正在鼓励在产品准入、培训和上市后监测方面采取更细緻的方法。这些地区的相关人员通常会在集中式参考检测能力与扩大分散式筛检的倡议之间取得平衡。在亚太地区，快速的都市化、多样化的实验室筛检以及积极的公共卫生筛检项目，支持加速采用即时诊断和核酸扩增技术。区域製造能力和物流考量进一步影响部署策略，使得跨区域伙伴关係和在地化工作对于确保供应连续性和满足多样化临床需求日益重要。

结合平台相容性、本地製造和综合服务的竞争策略和伙伴关係模式将提高可靠性和采用率。

活跃于结核病诊断领域的公司正透过产品改进、策略联盟和业务扩张等措施来应对不断变化的临床和供应链需求。成熟的诊断製造商持续投资于仪器和平台相容性、检测广度和服务模式，以降低医院和实验室客户的整体拥有成本。同时，规模较小的创新企业正专注于增强其利基产品，例如改进的样本製备工作流程、提高横向流动灵敏度以及只需极少操作员培训的承包照护现场解决方案。

诊断製造商、试剂製造商和物流供应商之间的合作日益普遍，整合产品将仪器、耗材和数位支援服务结合，从而提高了客户维繫和绩效可预测性。此外，各公司正优先考虑法规遵循和证据生成，以推动其在各个医疗保健系统中的采用。诸如本地製造伙伴关係、API 和试剂采购多元化以及对生命週期支援的承诺等策略性倡议，正成为供应商差异化的核心。对于采购和临床相关人员，供应商的选择标准如今已不再局限于分析性能，还包括供应链透明度、上市后支援能力以及在发生中断时快速检验替代采购方案的能力。

诊断产业领导者应采取切实可行的优先行动，以加强供应链、加速替代方案的检验，并使证据生成与临床状况保持一致

产业领导者应优先建构具有韧性的供应链，将短期缓解措施与长期策略协调相结合。首先，透过多元化供应商组合和检验关键试剂和耗材的次要来源，降低依赖单一来源的风险。其次，加快资格和性能检验通讯协定，确保能够及时引入替代供应商和本地生产线，避免不必要的延误。这些营运措施应与加强合约保护和库存策略相结合，以应对突发中断。

从商业性和临床角度来看，领导者应投资于针对特定终端使用者环境和样本类型的证据生成，重点关注医院、诊所和参考实验室的实际性能、工作流程整合和经济影响。此外，与区域製造商和物流合作伙伴达成合作协议可以缩短前置作业时间并减轻关税影响。最后，组织应加强连接临床营运、监管、采购和供应链团队的跨职能能力，以实现快速的情境规划和紧急计画执行。总而言之，这些建议将有助于结核病诊断运作的短期连续性和长期适应性。

我们透明、多方法的研究途径结合了主要专家访谈、供应链映射和监管整合，以提供可操作和检验的见解

本分析背后的调查方法结合了多源资料三角测量、专家访谈和供应链映射，从而提供了可靠的洞见。主要的定性资讯是透过与临床实验室主任、医院系统采购官员以及诊断公司高级研发和监管专家进行结构化访谈获得的，有助于深入了解营运重点和检验障碍。这些洞见与同期的监管指南文件和同行评审文献进行了交叉引用，以检验临床性能预期和技术权衡。

此外，我们还进行了供应链图谱绘製，以确定试剂、设备和物流的关键节点，并针对关税和本地製造方案的影响进行情境评估。数据整合强调假设的可重复性和可追溯性，研究结果经过内部同行评审，以确保关于采购行为、技术采用和监管回应的推论与观察到的实践一致。此调查方法支持基于证据的可操作建议，同时保持资料来源及其来源的透明度。

整合策略重点和业务要务，以确保在不断变化的技术和政策压力下诊断的连续性、临床准确性和可及性

摘要：结核病诊断领域正处于曲折点，技术进步、临床预期变化以及贸易政策等外部压力正在汇聚，重塑采购和部署选择。相关人员若能积极调整产品策略，使其与最终用户工作流程一致，实现供应链多元化，并投资于针对特定环境的客製化证据，将最有能力确保诊断的连续性并改善临床结果。

展望未来，持续的成功将取决于营运的适应性，包括快速检验替代供应商、整合临床适用的即时诊断解决方案以及协调监管和采购部门以避免不必要中断的能力。透过实施本文概述的策略和战术性建议，临床网路和诊断服务提供者可以增强其韧性，同时继续扩大及时且准确的结核病检测服务。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

  • 整合人工智慧的快速分子检测平台为偏远诊所的多重抗药性结核病检测提供了决策支援。
  • 在社区推广计画中扩大潜伏性结核感染的照护现场免疫诊断检测
  • 监管部门的核准和政府资金的增加加速了下一代基于 CRISPR 的结核病诊断测试的开发
  • 将智慧型手机显微镜与云端基础的数据分析结合，实现远端结核病涂片检测和监测
  • 扩展全自动样本到答案核酸扩增平台可减少高负荷区域的周转时间
  • 製药公司和公共卫生机构合作扩大都市区贫民窟的大规模筛检工作
  • 采用结合宿主免疫反应和病原体检测的多重生物标记组来提高结核病诊断的准确性
  • 建立利用行动实验室的分散式检查网络，以应对偏远地区的结核病疫情

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

8. 结核病检测市场（依检测类型）

  • 文化测试
    • 液体培养
    • 固态培养
  • 免疫学检测
    • 伊丽莎
    • 蛋白质印迹法
  • 分子检测
    • 线探针分析
    • PCR
  • 快速诊断测试
    • 层析法
    • 横向流动

9. 结核病检测市场（以最终用户划分）

  • 诊所
  • 医院
  • 参考实验室

10. 结核病检测市场（依技术）

  • 基于文化的技术
  • 免疫诊断
  • 脂阿拉伯甘露聚醣测定
  • 核酸增幅检查

第 11 章结核病检测市场（依样本类型）

  • 血
  • 痰
  • 尿

12. 结核病检测市场（依分销管道）

  • 诊断实验室
  • 医院药房
  • 网路药局

第十三章结核病检测市场（依应用）

  • 活动性结核病
  • 潜伏性结核病

14. 结核病检测市场（按地区）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第 15 章结核病检测市场（按群体）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国结核病检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章竞争格局

  • 2024年市占率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Cepheid, Inc.
    • QIAGEN NV
    • Hain Lifescience GmbH
    • Roche Diagnostics International Ltd
    • Abbott Laboratories
    • Becton Dickinson and Company
    • Bio-Rad Laboratories, Inc.
    • Thermo Fisher Scientific Inc.
    • Siemens Healthineers AG
    • bioMerieux SA
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market is projected to grow by USD 3.82 billion at a CAGR of 6.10% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 2.38 billion
Estimated Year [2025] USD 2.52 billion
Forecast Year [2032] USD 3.82 billion
CAGR (%) 6.10%

Comprehensive orientation to current tuberculosis diagnostic dynamics integrating clinical practice, technology pathways, supply considerations, and procurement priorities

This executive summary synthesizes critical developments shaping tuberculosis diagnostic practices, technology adoption, and end-user priorities across clinical pathways. It provides an integrated view of diagnostic modalities, regulatory shifts, distribution dynamics, and evolving operational pressures affecting laboratories, hospitals, and clinics. The narrative purposefully emphasizes practical implications for stakeholders who must align procurement, clinical workflows, and innovation roadmaps under intensified supply chain scrutiny.

By grounding the analysis in recent regulatory updates, supply chain patterns, and clinical guidance, this overview equips clinical leaders and commercial strategists with clear context for decision-making. It distinguishes between diagnostic approaches by test type and technology, and it clarifies how sample type and end-user settings influence test selection and utilization. Ultimately, the introduction sets a foundation for targeted recommendations and operational actions that follow, enabling organizations to prioritize resilience, diagnostic accuracy, and patient-centered access in their tuberculosis testing strategies.

How technological convergence, decentralization of testing, and changing clinical expectations are reshaping diagnostics and operational priorities across care settings

The landscape for tuberculosis diagnostics is undergoing transformative shifts driven by advances in molecular techniques, fluid sample testing innovations, and the acceleration of point-of-care solutions that shorten time-to-result. These technical evolutions are accompanied by changing clinical expectations: clinicians increasingly expect rapid, actionable results that can guide immediate therapeutic decisions and contact tracing interventions. As a result, diagnostic development is moving toward platforms that balance sensitivity with operational simplicity and faster turnaround.

Concurrently, the diagnostic ecosystem is adapting to new distribution and access models that prioritize decentralized testing. Reference laboratories remain central for complex assays, while hospitals and clinics increasingly seek rapid diagnostic platforms that can be integrated into routine workflows. Technology convergence is also notable: culture-based approaches continue to be refined while nucleic acid amplification technologies and immunodiagnostic methods are being optimized for broader use across diverse care settings. These shifts demand strategic alignment across R&D, regulatory affairs, and commercial operations to ensure that novel diagnostics meet both clinical and logistical requirements.

Tariff-driven supply chain adaptations and strategic sourcing shifts that reshaped procurement behavior, manufacturing footprints, and inventory resilience in diagnostic services

The introduction of enhanced United States tariff measures in 2025 created material perturbations across global diagnostic supply chains, particularly for components and consumables critical to tuberculosis testing workflows. Tariffs on imported reagents, assay kits, and select instrumentation increased landed costs and amplified the importance of procurement agility. As a direct consequence, laboratories and hospital procurement teams revisited supplier portfolios and contractual terms to mitigate near-term cost impacts and to preserve test continuity.

In response, many organizations expanded localized sourcing strategies and accelerated qualification processes for alternative suppliers to reduce dependence on tariff-affected import routes. This pivot prompted a re-examination of inventory policies and a shift toward strategic stockholding for high-use consumables such as nucleic acid extraction kits and culture media. At the same time, manufacturers faced pressure to reassess their global production footprints, with several prioritizing regional manufacturing investments or contract manufacturing arrangements to circumvent tariff exposure. Regulatory pathways and supply validations became focal points, since alternate suppliers and newly localized production lines required timely but rigorous performance verification. Taken together, these adjustments underscore the need for resilient procurement practices, diversified supplier ecosystems, and integrated regulatory planning to navigate tariff-driven disruptions while maintaining diagnostic reliability and clinical continuity.

Integrated segmentation framework linking test modalities, end-user needs, sample logistics, and distribution channels to prioritize clinical and commercial strategies

Understanding segmentation is essential to align product development, commercialization, and clinical adoption strategies across the tuberculosis diagnostic continuum. When evaluating test types, stakeholders must differentiate among culture tests, immunological assays, molecular diagnostics, and rapid diagnostic tests; within these, there are important subtypes such as liquid and solid culture methods, ELISA and Western blot immunoassays, line probe assays and PCR within molecular testing, and chromatographic and lateral flow techniques among rapid diagnostics. These distinctions affect throughput, technical skill requirements, and compatibility with existing laboratory infrastructure, and they therefore guide where investments in automation and training will deliver the greatest operational returns.

End-user segmentation further refines prioritization because clinics, hospitals, and reference laboratories have divergent needs for turnaround time, batch processing, and complexity tolerance. Technology segmentation-spanning culture-based techniques, immunodiagnostics, lipoarabinomannan assays, and nucleic acid amplification tests-frames the product innovation pathway and regulatory strategy, as different technologies face distinct validation demands and clinical evidence thresholds. Sample type considerations, including blood, sputum, and urine, influence specimen collection logistics, biosafety protocols, and the suitability of point-of-care versus centralized testing. Distribution channel dynamics such as diagnostic laboratories, hospital pharmacies, and online pharmacy models shape procurement cycles and reimbursement touchpoints. Finally, application segmentation between active and latent tuberculosis demands different performance characteristics and interpretive frameworks. By integrating these segmentation layers, stakeholders can prioritize investments, define go-to-clinic deployment models, and tailor evidence generation to the settings and use cases that matter most.

How regional regulatory harmonization, infrastructure variability, and public health priorities drive differentiated adoption pathways and supply strategies across global regions

Regional dynamics influence both the adoption pathway of diagnostic technologies and the operational imperatives that providers face. Across the Americas, there is strong emphasis on consolidating laboratory networks, ensuring regulatory alignment for assay approvals, and integrating diagnostics into broader public health initiatives. These priorities shape procurement timelines and the demand for validated, interoperable solutions compatible with existing laboratory information systems.

In Europe, the Middle East & Africa, regulatory harmonization efforts and varying healthcare financing models prompt a more nuanced approach to product entry, training, and post-market surveillance. Stakeholders in these regions often balance centralized reference testing capabilities with initiatives to expand decentralized screening. Across Asia-Pacific, rapid urbanization, varied laboratory infrastructure, and aggressive public health screening programs support accelerated adoption of point-of-care and nucleic acid amplification technologies. Regional manufacturing capacity and logistics considerations further influence deployment strategies, so cross-regional partnerships and localization efforts are increasingly important to ensure continuity of supply and to meet diverse clinical needs.

Competitive strategies and partnership models that combine platform compatibility, localized production, and integrated services to strengthen reliability and adoption

Companies active in tuberculosis diagnostics are pursuing a mix of product refinement, strategic partnerships, and operational expansion to address evolving clinical and supply chain demands. Established diagnostic manufacturers continue to invest in instrument-platform compatibility, assay breadth, and service models that reduce total cost of ownership for hospital and laboratory customers. At the same time, smaller innovators are focusing on niche product enhancements, including improved sample preparation workflows, lateral flow sensitivity gains, and turnkey point-of-care solutions that require minimal operator training.

Collaborations between diagnostics firms, reagent suppliers, and logistics providers are increasingly common, as integrated offers combining instrumentation, consumables, and digital support services improve customer retention and performance predictability. Moreover, companies are emphasizing regulatory readiness and evidence generation to facilitate adoption across diverse healthcare systems. Strategic moves such as localized manufacturing partnerships, API and reagent sourcing diversification, and lifecycle support commitments are central to vendor differentiation. For procurement and clinical stakeholders, vendor selection criteria now extend beyond analytical performance to include supply chain transparency, post-market support capabilities, and the ability to rapidly validate alternative sourcing options when disruptions occur.

Practical and prioritized actions for diagnostics leaders to harden supply chains, accelerate validation of alternatives, and align evidence generation with care settings

Industry leaders should prioritize building resilient supply chains that combine near-term mitigation with long-term strategic alignment. First, diversify supplier portfolios and validate secondary sources for critical reagents and consumables to reduce single-source exposure. Second, accelerate qualification and performance verification protocols so that alternate suppliers and localized production lines can be onboarded without unnecessary delay. These operational moves should be paired with enhanced contractual protections and inventory strategies to cushion against episodic disruptions.

From a commercial and clinical perspective, leaders should invest in evidence generation targeted to specific end-user settings and sample types, focusing on real-world performance, workflow integration, and economic implications within hospitals, clinics, and reference laboratories. Additionally, pursuing collaborative agreements with regional manufacturers and logistics partners can shorten lead times and reduce tariff sensitivity. Finally, organizations should strengthen cross-functional capabilities-linking clinical affairs, regulatory, procurement, and supply chain teams-to enable rapid scenario planning and implementation of contingency actions. Taken together, these recommendations support both short-term continuity and long-term adaptability in tuberculosis diagnostic operations.

Transparent multi-method research approach combining primary expert interviews, supply chain mapping, and regulatory synthesis to deliver actionable and verifiable insights

The research approach underpinning this analysis combined multi-source data triangulation, expert interviews, and supply chain mapping to ensure robust insights. Primary qualitative inputs were obtained through structured interviews with clinical laboratory directors, procurement leads in hospital systems, and senior R&D and regulatory professionals within diagnostic firms, enabling a grounded understanding of operational priorities and validation hurdles. These insights were cross-referenced with contemporaneous regulatory guidance documents and peer-reviewed literature to validate clinical performance expectations and technology trade-offs.

Additionally, supply chain mapping exercises identified critical nodes for reagents, instrumentation, and logistics, which informed scenario assessments around tariff impacts and localized manufacturing options. Data synthesis emphasized reproducibility and traceability of assumptions, and findings were subjected to internal peer review to ensure that inferences about procurement behavior, technology adoption, and regulatory readiness were consistent with observed practices. This methodology supports actionable, evidence-based recommendations while maintaining transparency in data sources and analytic steps.

Synthesis of strategic priorities and operational imperatives to secure diagnostic continuity, clinical accuracy, and access amid evolving technological and policy pressures

In summary, the tuberculosis diagnostic environment is at an inflection point where technological progress, shifting clinical expectations, and external pressures such as trade policy converge to reshape procurement and deployment choices. Stakeholders who proactively align product strategies with end-user workflows, diversify supply chains, and invest in evidence tailored to specific settings will be best positioned to ensure diagnostic continuity and to improve clinical outcomes.

Looking ahead, durable success will depend on operational adaptability: the ability to validate alternate suppliers quickly, to integrate point-of-care solutions where clinically appropriate, and to coordinate across regulatory and procurement functions to avoid unnecessary disruption. By implementing the strategic and tactical recommendations outlined herein, clinical networks and diagnostic providers can strengthen resilience while continuing to expand access to timely and accurate tuberculosis testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid molecular testing platforms integrated with AI enabled decision support for multi drug resistant TB detection in remote clinics
  • 5.2. Expansion of point of care immunodiagnostic assays targeting latent tuberculosis infection detection in community outreach programs
  • 5.3. Increased regulatory approvals and government funding incentives accelerating development of next generation CRISPR based TB diagnostic tests
  • 5.4. Integration of smartphone microscopy and cloud based data analytics for remote tuberculosis smear examination and monitoring
  • 5.5. Scaling of fully automated sample to answer nucleic acid amplification platforms to reduce turnaround time in high burden regions
  • 5.6. Collaboration between pharmaceutical companies and public health agencies to expand mass screening initiatives in urban slums
  • 5.7. Adoption of multiplexed biomarker panels combining host immune response and pathogen detection for improved TB diagnosis accuracy
  • 5.8. Implementation of decentralized testing networks utilizing mobile laboratories to address TB outbreaks in remote communities

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Testing Market, by Test Type

  • 8.1. Culture Test
    • 8.1.1. Liquid Culture
    • 8.1.2. Solid Culture
  • 8.2. Immunological Test
    • 8.2.1. Elisa
    • 8.2.2. Western Blot
  • 8.3. Molecular Test
    • 8.3.1. Line Probe Assay
    • 8.3.2. Pcr
  • 8.4. Rapid Diagnostic Test
    • 8.4.1. Chromatographic
    • 8.4.2. Lateral Flow

9. Tuberculosis Testing Market, by End User

  • 9.1. Clinics
  • 9.2. Hospitals
  • 9.3. Reference Laboratory

10. Tuberculosis Testing Market, by Technology

  • 10.1. Culture Based Technology
  • 10.2. Immunodiagnostic
  • 10.3. Lipoarabinomannan Assay
  • 10.4. Nucleic Acid Amplification Test

11. Tuberculosis Testing Market, by Sample Type

  • 11.1. Blood
  • 11.2. Sputum
  • 11.3. Urine

12. Tuberculosis Testing Market, by Distribution Channel

  • 12.1. Diagnostic Laboratory
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy

13. Tuberculosis Testing Market, by Application

  • 13.1. Active Tuberculosis
  • 13.2. Latent Tuberculosis

14. Tuberculosis Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Tuberculosis Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Tuberculosis Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Cepheid, Inc.
    • 17.3.2. QIAGEN N.V.
    • 17.3.3. Hain Lifescience GmbH
    • 17.3.4. Roche Diagnostics International Ltd
    • 17.3.5. Abbott Laboratories
    • 17.3.6. Becton Dickinson and Company
    • 17.3.7. Bio-Rad Laboratories, Inc.
    • 17.3.8. Thermo Fisher Scientific Inc.
    • 17.3.9. Siemens Healthineers AG
    • 17.3.10. bioMerieux SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GCC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. G7 TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. NATO TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 32. TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025-2032 (USD MILLION)
  • TABLE 299. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 301. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2024 (USD MILLION)
  • TABLE 304. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2025-2032 (USD MILLION)
  • TABLE 305. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2024 (USD MILLION)
  • TABLE 306. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2025-2032 (USD MILLION)
  • TABLE 307. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2024 (USD MILLION)
  • TABLE 308. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2025-2032 (USD MILLION)
  • TABLE 309. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2024 (USD MILLION)
  • TABLE 310. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2025-2032 (USD MILLION)
  • TABLE 311. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 312. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 313. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 315. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 316. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 317. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 318. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 319. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 320. MIDDLE EAST TUBERCULOSIS TESTIN